Oropharyngeal candidiasis in the era of antiretroviral therapy
- PMID: 20156694
- PMCID: PMC2843789
- DOI: 10.1016/j.tripleo.2009.11.026
Oropharyngeal candidiasis in the era of antiretroviral therapy
Abstract
Oropharyngeal candidiasis (OPC) remains a common problem in the HIV-infected population despite the availability of antiretroviral therapy (ART). Although Candida albicans is the most frequently implicated pathogen, other Candida species also may cause infection. The emergence of antifungal resistance within these causative yeasts, especially in patients with recurrent oropharyngeal infection or with long-term use of antifungal therapies, requires a working knowledge of alternative antifungal agents. Identification of the infecting organism and antifungal susceptibility testing enhances the ability of clinicians to prescribe appropriate antifungal therapy. Characterization of the responsible mechanisms has improved our understanding of the development of antifungal resistance and could enhance the management of these infections. Immune reconstitution has been shown to reduce rates of OPC, but few studies have evaluated the current impact of ART on the epidemiology of OPC and antifungal resistance in these patients. Preliminary results from an ongoing clinical study showed that in patients with advanced AIDS, oral yeast colonization was extensive, occurring in 81.1% of the 122 patients studied, and symptomatic infection occurred in one-third. In addition, resistant yeasts were still common, occurring in 25.3% of patients colonized with yeasts or with symptomatic infection. Thus, OPC remains a significant infection in advanced AIDS, even with ART. Current knowledge of the epidemiology, pathogenesis, clinical presentation, treatment, and mechanisms of antifungal resistance observed in OPC are important in managing patients with this infection and are the focus of this review.
Published by Mosby, Inc.
Figures



Similar articles
-
The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients.Spec Care Dentist. 2000 Sep-Oct;20(5):178-81. doi: 10.1111/j.1754-4505.2000.tb00015.x. Spec Care Dentist. 2000. PMID: 11203894
-
Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.J Oral Pathol Med. 2001 Sep;30(8):481-8. doi: 10.1034/j.1600-0714.2001.030008481.x. J Oral Pathol Med. 2001. PMID: 11545239
-
Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.Afr Health Sci. 2008 Sep;8(3):142-8. Afr Health Sci. 2008. PMID: 19357740 Free PMC article.
-
Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment.AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1405-12. doi: 10.1089/088922299309900. AIDS Res Hum Retroviruses. 1999. PMID: 10555102 Review.
-
A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):170-9. doi: 10.1067/moe.2001.116600. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001. PMID: 11505264
Cited by
-
Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials.Saudi Pharm J. 2021 Apr;29(4):315-323. doi: 10.1016/j.jsps.2021.03.003. Epub 2021 Mar 24. Saudi Pharm J. 2021. PMID: 33994826 Free PMC article.
-
Targeting Candida albicans filamentation for antifungal drug development.Virulence. 2017 Feb 17;8(2):150-158. doi: 10.1080/21505594.2016.1197444. Epub 2016 Jun 7. Virulence. 2017. PMID: 27268130 Free PMC article. Review.
-
Competitive Interactions between C. albicans, C. glabrata and C. krusei during Biofilm Formation and Development of Experimental Candidiasis.PLoS One. 2015 Jul 6;10(7):e0131700. doi: 10.1371/journal.pone.0131700. eCollection 2015. PLoS One. 2015. PMID: 26146832 Free PMC article.
-
Antifungal efficacy of herbs.J Oral Biol Craniofac Res. 2019 Jan-Mar;9(1):28-32. doi: 10.1016/j.jobcr.2018.06.002. Epub 2018 Jun 7. J Oral Biol Craniofac Res. 2019. PMID: 30197861 Free PMC article.
-
Effects of benzydamine and mouthwashes containing benzydamine on Candida albicans adhesion, biofilm formation, regrowth, and persistence.Clin Oral Investig. 2022 Apr;26(4):3613-3625. doi: 10.1007/s00784-021-04330-8. Epub 2022 Jan 23. Clin Oral Investig. 2022. PMID: 35066687 Free PMC article.
References
-
- Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351(9102):543–9. - PubMed
-
- Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS (London, England) 1998;12(4):447–8. - PubMed
-
- Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS (London, England) 1998;12(18):2511–3. - PubMed
-
- Kerdpon D, Pongsiriwet S, Pangsomboon K, Iamaroon A, Kampoo K, Sretrirutchai S, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral diseases. 2004;10(3):138–44. - PubMed
-
- Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. The New England journal of medicine. 1984;311(6):354–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical